InMed Pharmaceuticals (NASDAQ: INM) is a trailblazer, a pioneer defining the value of rare cannabinoids in the pharmaceutical sector and just how integral they are in pushing the industry forward. The global cannabis market is experiencing tremendous growth, particularly considering there are over 100 known cannabinoids, including rare ones that are quickly taking over and will soon dominate the market. The potency of rare cannabinoids has given them powerful health benefits, hence their demand within the cosmetics, food and beverage, health and wellness, and pharmaceutical sectors. “InMed’s most advanced compound, INM-755, has already proven helpful in treating epidermolysis bullosa, a severe genetic disorder… InMed is also working on its INM-008 compound for the treatment of glaucoma and is currently evaluating different formulations to deliver ocular cannabinoids into the eye,” a recent article reads. “InMed is not just focusing on rare cannabinoid research but also investing time and resources into its manufacturing process. So far, this process allows for cannabinoid synthesis to create compounds in the laboratory that are bioidentical to those derived from the cannabis plant.”
To view the full article, visit https://ibn.fm/8DeTk
About InMed Pharmaceuticals Inc.
InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary, BayMedica, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is also a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.InMedPharma.com and www.BayMedica.com.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
